Department of Economics, Universitat de Barcelona, Barcelona, Spain.
BCN Health Economics & Outcomes Research S.L., Barcelona, Spain.
PLoS One. 2024 Mar 7;19(3):e0298764. doi: 10.1371/journal.pone.0298764. eCollection 2024.
The goal of this study is to determine the medical costs, comorbidity profile, and health care resources use of patients diagnosed with prostate cancer who have been treated in Spanish hospitals.
The admission records of the patients diagnosed with prostate cancer used in the study were registered between January 2016 and December 2020. These records have been collected from a Spanish hospital discharge database and have been evaluated in a retrospective multicenter analysis.
8218 patients from the database met the criteria and were thus analyzed. The median aged of the diagnosed patients was 71.68 years. The median Charlson comorbidity index (CCI) score was 4, and the updated median CCI was 3. Hypertension was diagnosed in the 49.76% of the individuals, 37.03% had chronic obstructive pulmonary disease and 34.51% had hyperlipidaemia. The mortality rate was 9.30%. The most common medical procedure was prostate resection with percutaneous endoscopic approach (31.18%). The mean annual cost per admission was 5212.98€ €.
Technologies, such as the prostate-specific antigen (PSA) testing for screening has helped in the diagnosis in the past decades, enhancing a decrease in the mortality rate of the patients throughout the years.
本研究的目的是确定在西班牙医院接受治疗的前列腺癌患者的医疗费用、合并症概况和医疗资源利用情况。
本研究中使用的前列腺癌患者的入院记录是在 2016 年 1 月至 2020 年 12 月期间登记的。这些记录是从一家西班牙医院出院数据库中收集的，并进行了回顾性多中心分析。
数据库中有 8218 名患者符合标准并进行了分析。诊断患者的中位年龄为 71.68 岁。中位 Charlson 合并症指数（CCI）评分为 4，更新的中位 CCI 评分为 3。49.76%的个体被诊断为高血压，37.03%的个体患有慢性阻塞性肺疾病，34.51%的个体患有高脂血症。死亡率为 9.30%。最常见的医疗程序是经皮内镜前列腺切除术（31.18%）。每次住院的平均年度费用为 5212.98 欧元。
过去几十年，前列腺特异性抗原（PSA）检测等技术已用于筛查，有助于提高诊断率，降低患者的死亡率。
